Residual risk and high-density lipoprotein cholesterol levels: is there a relationship?

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Pharmacology

Background:

• Statins are effective in reducing cardiovascular events for primary and secondary prevention.
• A significant residual cardiovascular risk remains despite statin therapy.
• Low high-density lipoprotein (HDL) cholesterol levels are a key contributor to this residual risk.

Purpose of the Study:

• To explore HDL-based interventions as a novel therapeutic strategy.
• To address the unmet need in atherosclerosis management beyond statins.
• To investigate methods for raising HDL cholesterol or enhancing HDL function.

Main Methods:

• Review of current literature on statin efficacy and residual risk.
• Analysis of studies investigating HDL cholesterol-raising therapies.
• Examination of research on improving HDL functionality.
• Focus on emerging therapeutic targets for atherosclerosis.

Main Results:

• Residual cardiovascular risk is significantly associated with low HDL cholesterol.
• Current statin therapy does not adequately address this HDL-related risk.
• HDL-based interventions show promise in further reducing cardiovascular events.
• Enhancing HDL function may be as important as raising HDL levels.

Conclusions:

• Targeting HDL cholesterol represents a promising next step in cardiovascular disease prevention.
• Interventions aimed at increasing HDL levels or improving its function are warranted.
• Further research into HDL-based therapies is essential for comprehensive atherosclerosis management.